LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.61 -4.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.6099999999999999

Max

1.73

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	103
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+126.63% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	60M 712M
Eelmine avamishind	5.78
Eelmine sulgemishind	1.61

Uudiste sentiment

By Acuity

72%

28%

317 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. märts 2026, 21:37 UTC

Omandamised, ülevõtmised, äriostud

Lensar and Alcon Agree to Terminate Merger

16. märts 2026, 19:06 UTC

Uudisväärsed sündmused

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16. märts 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16. märts 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. märts 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Oil Prices Decline -- Market Talk

16. märts 2026, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16. märts 2026, 23:05 UTC

Market Talk

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16. märts 2026, 21:56 UTC

Market Talk

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16. märts 2026, 21:41 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

16. märts 2026, 21:41 UTC

Market Talk

Uudisväärsed sündmused

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16. märts 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16. märts 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16. märts 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16. märts 2026, 20:57 UTC

Omandamised, ülevõtmised, äriostud

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16. märts 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

16. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. märts 2026, 19:53 UTC

Uudisväärsed sündmused

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16. märts 2026, 19:43 UTC

Market Talk

Global Equities Roundup: Market Talk

16. märts 2026, 19:43 UTC

Market Talk

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16. märts 2026, 19:37 UTC

Market Talk

Uudisväärsed sündmused

Natural Gas Follows Oil Prices Lower -- Market Talk

16. märts 2026, 19:20 UTC

Uudisväärsed sündmused

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16. märts 2026, 19:17 UTC

Market Talk

Uudisväärsed sündmused

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16. märts 2026, 19:00 UTC

Market Talk

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16. märts 2026, 18:23 UTC

Market Talk

LME Restarts Trading After Outage -- Market Talk

16. märts 2026, 17:36 UTC

Uudisväärsed sündmused

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16. märts 2026, 17:19 UTC

Market Talk

Grains Sink as Investors Steer Toward Equities -- Market Talk

16. märts 2026, 17:14 UTC

Uudisväärsed sündmused

Trump Ends News Conference

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

126.63% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 126.63%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

317 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.